| 1.01 1.01 (100%) | 03-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Procaps Group S.A., established in Luxembourg in 1977, functions as a global pharmaceutical enterprise dedicated to the creation, production, and distribution of a broad spectrum of pharmaceutical solutions. The company manufactures and markets branded prescription medications addressing diverse therapeutic needs, including women's health, pain management, dermatological conditions, digestive disorders, growth and development, cardiovascular care, vision health, central nervous system ailments, and respiratory issues. In addition to prescription drugs, Procaps supplies a suite of products for hospital use, encompassing antibiotics, anticoagulants, personal protective equipment, immunosuppressants, oncology treatments, and analgesics. Its consumer healthcare division offers an extensive portfolio of over-the-counter (OTC) products across approximately eight primary therapeutic areas such as gastrointestinal health, skincare, cough and cold remedies, pain relievers, urological support, and a variety of vitamins, minerals, and dietary supplements. These offerings cover specific categories like anti-infectives, cardiovascular health, hormonal treatments, metabolic and endocrine support, nervous system medications, ophthalmic solutions, osteoarticular products, and more. Complementing its drug offerings, Procaps provides various diabetes management solutions, including blood glucose meters, telemonitoring devices, oral anti-diabetic medications, cosmeceuticals, and insulin delivery systems. The company also extends its expertise to third-party pharmaceutical companies through contract drug development and manufacturing services, with a particular specialization in soft gelatin capsule technologies.
Thu, 24 Apr 2025
PROC Stock Price, News & Analysis - Stock Titan
Mon, 03 Feb 2025
Procaps Group Receives Delisting Notice From Nasdaq - Yahoo Finance UK
Tue, 14 May 2024
Procaps Group Delays Filing of Annual Report on Form 20-F - The AI Journal
Wed, 29 Nov 2023
Procaps Group and Genomma Lab Announce a Strategic Agreement to Manufacture and Market Softgel Products in Latin America - Business Wire
Mon, 30 Oct 2023
Procaps Group Wins First Place in Ranking of Innovative Companies in the Pharma Sector in Colombia - Business Wire
Tue, 03 Jan 2023
Procaps Group Announces Termination of Acquisition Agreement with Grupo Somar - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|